Marcin Dembek

Title: Marcin Dembek: Innovator in HIV Therapeutics

Introduction

Marcin Dembek is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of immunotherapy, particularly in the development of specific binding molecules for HIV treatment. His innovative work has the potential to improve the lives of individuals infected with HIV.

Latest Patents

Dembek holds a patent for HIV specific binding molecules. This patent includes specific binding molecules, such as T cell receptors (TCRs), that bind the HLA-A*02 restricted peptide SLYNTVATL derived from the HIV Gag gene product, p17. The TCRs in this invention feature non-natural mutations within the alpha and/or beta variable domains compared to a native TCR. These specific binding molecules exhibit improved stability and yield while retaining advantageous properties. They are particularly useful in developing soluble immunotherapeutic reagents for treating HIV-infected individuals. He has 1 patent to his name.

Career Highlights

Marcin Dembek is associated with Immunocore Limited, a company focused on innovative immunotherapy solutions. His work at Immunocore has positioned him as a key player in the fight against HIV, contributing to advancements in therapeutic strategies.

Collaborations

Dembek collaborates with talented individuals such as Luis Filipe Da Silva Godinho and Praveen Singh. These collaborations enhance the research and development efforts within the company, fostering innovation in the field.

Conclusion

Marcin Dembek's contributions to HIV therapeutics through his innovative patents and collaborations highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in immunotherapy, offering hope for improved treatments for HIV-infected individuals.